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Abstract
X-linked adrenoleukodystrophy (X-ALD) is characterized by marked phenotypic variation ranging from adrenomyeloneuro-
pathy (AMN) to childhood cerebral ALD (CCALD). X-ALD is caused by mutations in the ABCD1 gene, but no genotype-
phenotype correlation has been established so far and modifier gene variants are suspected to modulate phenotypes.
Specific classes of lipids, enriched in very long-chain fatty acids that accumulate in plasma and tissues from X-ALD patients
are suspected to be involved in the neuroinflammatory process of CCALD. CD1 proteins are lipid- antigen presenting
molecules encoded by five CD1 genes in human (CD1A-E). Association studies with 23 tag SNPs covering the CD1 locus was
performed in 52 patients with AMN and 87 patients with CCALD. The minor allele of rs973742 located 4-kb downstream
from CD1D was significantly more frequent in AMN patients (x
2=7.6; P=0.006). However, this association was no longer
significant after Bonferroni correction for multiple testing. The other polymorphisms of the CD1 locus did not reveal
significant association. Further analysis of other CD1D polymorphisms did not detect stronger association with X-ALD
phenotypes. Although the association with rs973742 warrants further investigations, these results indicate that the genetic
variants of CD1 genes do not contribute markedly to the phenotypic variance of X-ALD.
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Introduction
X-linked adrenoleukodystrophy (X-ALD; MIM# 300100) is
a progressive neurodegenerative disease that is caused by
mutations in the ABCD1 gene, encoding ALD protein (ALDP),
an (ATP)-binding-cassette (ABC) transporter located in the
peroxisomal membrane [1]. Based on cross complementation in
yeast, it is suggested that ALDP is active as a homodimer and is
involved in the transport of very long-chain fatty (VLCF) acyl-
C o Ae s t e r sa c r o s st h ep e r o x i s o m a lm e m b r a n e[ 2 ] .A L D P
deficiency results in increased levels of VLCFacyl-CoA esters
in the cytosol and consequently all X-ALD patients accumulate
saturated straight very-long-chain fatty acids (VLCFA) in their
plasma and tissues [3]. The disease affects the cerebral white
matter, axons in the spinal cord, peripheral nerves, adrenal
cortex and testis [4]. X-ALD is characterized clinically by a
striking and unpredictable variation of neurologic phenotype,
ranging from the rapidly progressive childhood cerebral form
(CCALD) to adrenomyeloneuropathy (AMN) that affects only
the spinal cord in adults. Analysis of the ABCD1 gene in X-ALD
patients has revealed a wide variability of ABCD1 mutations,
with virtually one different mutation per family, without
correlation with the few recurrent mutations and X-ALD
phenotype (http://www.x-ald.nl) [4,5]. Moreover, as X-ALD
males in the same family may express different phenotypes, it is
clear that mutations of the ABCD1 gene does not account for
the disease variability. No correlation between X-ALD phe-
notype and levels of VLCFA accumulation observed in plasma
and fibroblasts from X-ALD patients has been demonstrated
either.
Patients with AMN develop progressive spastic paraparesis
in adulthood, sometimes associated with peripheral nerve
involvement. The neuropathology of AMN is mostly charac-
terized by axonal loss in the long tracts of the spinal cord,
mainly dorsal fascicles and pyramidal tracts, without significant
inflammatory changes [6]. By contrast, boys with CCALD de-
velop a devastating neurologic disease that leads to vegetative
stage or death in few years [6]. The neuropathology of CCALD
is characterized by severe degeneration of the white matter
within the brain, loss of oligodendrocytes, reactive astrocytosis
and secondary axonal loss. A most striking change of CCALD
is the presence of inflammatory infiltrates at the border of the
lesions of the white matter, just behind the active demyelin-
ating front. Inflammatory cells are CD4
+ and CD8
+ T
lymphocytes, some of them containing granzyme B, and rare
B lymphocytes [7].
The phenotypic variation of X-ALD is likely caused by the
combination of environmental and/or genetic factors. Genetic
segregation analysis provided support for the hypothesis that at
least one autosomal gene plays a role in the clinical variation of
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patients with CCALD are unknown but it has been speculated
that specific classes of lipids enriched in VLCFA could be
involved this process [9]. In addition, CD1b-immunoreactive
astrocytes and strongly CD1c-immunoreactive perivascular and
scattered interstitial cells, presumably microglia, are frequently
observed in the demyelinating lesions of patients with CCALD
[7]. CD1b and CD1c belong to a group of antigen-presenting
molecules that can present lipid antigens to immunocompetent T
cells [10]. CD1d molecules present glycolipid antigens to a
specialized subset of T cells known as natural killer T (NKT) cells
[10]. Type I NKT cells (also known as invariant or semi-invariant
NKT, iNKT cells) express an invariant T-cell receptor (TCR) a-
chain in combination with certain Va chains. This TCR permits
iNKT cells to recognize both self and microbial glycolipid
antigens in the context of CD1d molecules [10]. Converging data
support the role of iNKT cells in the inflammatory cerebral
demyelinating diseases [11]. In humans, five genes (CD1A-E)
located within 200-kb on chromosome 1q22-q23 encodes CD1a,
CD1b, CD1c, CD1d and CD1e lipid antigen-presenting
molecules. Polymorphic variants of one or several of these CD1
molecules could affect lipid presentation and, in the context of
impaired metabolism of VLCFA as observed in X-ALD, may
contribute to trigger the neuroinflammation process. To test this
hypothesis, we assessed the association of variants in the CD1
genes cluster encompassing the five human CD1 genes in a
population of 139 X-ALD patients presenting either CCALD or
pure form of AMN.
Results
Tagging of the CD1 locus and association analyses of
selected tag SNPs in CCALD and AMN patients
We first analyzed the LD pattern in a region of 400-kb centered
on CD1 genes. We observed that the five CD1 genes were included
in a single block of linkage disequilibrium (LD), thus excluding LD
of CD1 genes polymorphisms with polymorphisms of surrounding
genes (data not shown). We then focused on the 200-kb region
encompassing the five CD1 genes and selected 23 tag SNPs to
cover the common genetic variation of the CD1 genes cluster.
A non-synonymous SNP of CD1A (rs2269715, p.Cys68Trp) and
a SNP located 3-kb upstream CD1C (rs12033535) were excluded
from further analyses because their minor allele frequencies
(MAFs) were ,0.05. The remaining 21 SNPs were analyzed in
AMN and CCALD patients (Table 1). Only three tag SNPs
showed evidence of allelic associations with X-ALD phenotypes at
a 0.05 significance level (Table 1): rs973742 G/A (x
2=7.6;
P=0.006; empirical P=0.008) located 4-kb downstream from the
39 region of CD1D; rs3181082 C/T (x
2=5.3; P=0.028; empirical
P=0.031) and rs2317955 G/T (x
2=4.4; P=0.043; empirical
P=0.054) which are in LD (r
2=0.96), and located in the upstream
region of CD1B (at 1- and 14-kb respectively). For rs973742,
rs3181082 and rs2317955, the minor alleles were more frequent in
AMN than CCALD patients (Table 1). For rs973742, both the
asymptotic (P=0.006) and empirical P value (P=0.008) are closed
from the threshold required to keep a type I error rate at 0.05 after
Bonferroni correction (Bonferroni-corrected significance thresh-
Table 1. Allelic analyses of the 23 tag SNPs genotyped in CCALD and AMN patients.
SNP (dbSNP31) MAF MAF AMN MAF CCALD x
2 P value empirical P value
b Odds ratio [CI95%]
rs3021477 0.39 0.41 0.38 0.32 0.573 - 0.87 [0.53 ; 1.42]
rs3754471 0.49 0.43 0.53 2.4 0.121 - 1.47 [0.90 ; 2.40]
rs859010 0.08 0.13 0.06 3.91 0.069
a 0.064 0.42 [0.18 ; 1.01]
rs692565 0.41 0.42 0.41 0.06 0.805 - 0.94 [0.57 . 1.54]
rs1748363 0.15 0.19 0.13 2.2 0.138 - 0.61 [0.31 ; 1.18]
rs973742 0.40 0.50 0.33 7.56 0.006 0.008 0.50 [0.30 ; 0.82]
rs429201 0.16 0.20 0.13 2.38 0.123 - 0.60 [0.32 ; 1.15]
rs366316 0.16 0.17 0.14 0.43 0.512 - 0.80 [0.41 ; 1.55]
rs2269715 0.04 0.07 0.02 - - - -
rs440419 0.19 0.24 0.16 2.26 0.133 - 0.63 [0.35 ; 1.15]
rs1230716 0.41 0.44 0.39 0.88 0.347 - 0.79 [0.48 ; 1.29]
rs12033535 0.03 0.03 0.03 - - - -
rs1590230 0.16 0.16 0.16 0.003 0.956 - 0.98 [0.51 ; 1.90]
rs10797007 0.28 0.34 0.24 2.94 0.086 0.117 0.62 [0.67 ; 1.07]
rs3181082 0.11 0.16 0.07 5.33 0.028
a 0.031 0.41 [0.19 ; 0.89]
rs2317955 0.10 0.15 0.08 4.36 0.043
a 0.054 0.44 [0.20 ; 0.97]
rs1065457 0.28 0.33 0.25 2.07 0.15 - 0.68 [0.40 ; 1.15]
rs12742463 0.08 0.10 0.08 0.39 0.654
a - 0.76 [0.32 ; 1.80]
rs12139388 0.08 0.09 0.08 0.03 1
a - 0.92 [0.39 ; 2.22]
rs11801558 0.08 0.08 0.08 0.005 1
a - 0.97 [0.39 ; 2.42]
rs7547997 0.11 0.11 0.11 0.06 1
a - 1.10 [0.50 ; 2.39]
rs11264965 0.18 0.19 0.17 0.29 0.587 - 0.84 [0.45 ; 1.58]
rs12756570 0.06 0.06 0.05 0.29 0.589 - 0.76 [0.27 ; 2.09]
a: The Fisher’s exact test was used for SNP with a Minor Allele Frequency (MAF),0.10.
b: Permutation-based empirical P value were calculated for SNP showing a trend of association (P value,0.10).
doi:10.1371/journal.pone.0029872.t001
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rs3181082 are located in the CD1D and CD1B gene region,
respectively, we analyzed the LD pattern of the 21 tag SNPs
included in the association analysis (Figure 1). There was no LD
between the most associated tag SNPs located in CDID and CD1B
(rs973742 and rs3181082, r
2=0).
Figure 1. Tagging of the CD1 locus. A) Allelic association results of the tag SNPs genotyped in CCALD and AMN patients: each black dot
represents a tag SNP; -log10P is plotted for each of the 21 tag SNPs; the five CD1 genes are indicated by black boxes; B) LD between the
corresponding tag SNPs: LD is represented by shades of grey as a function of r
2 values (black diamond for r
2$0.90, white diamond for r
2=0).
Associated tag SNPs are marked with an asterisk.
doi:10.1371/journal.pone.0029872.g001
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genes in controls
CD1D and CD1B genes, including the 59 and 39UTRs, were then
sequenced in 50 control individuals to identify potential new
variants. All SNPs identified were already described and referenced
in dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/).
The MAF of detected variants is indicated in Table S1.
Association analyses of CD1D and CD1B variants in
CCALD and AMN patients
Ten additional common SNPs with a MAF.0.05 (four for the
CD1D gene and six for the CD1B gene) were further genotyped in
AMN and CCALD patients. Despite a low MAF (,0.05), three
SNPs (rs11583390, rs35841099 and rs62642468) of the CD1B
gene were kept in this study given their potential functionality
(missense variants or located in the 39 UTR).
All variants detected in our control population were also
detected in the X-ALD population. These included in particular
the two missense variants of CD1B but both of them had a low
MAF (#0.03), precluding any possibility to reach significance level
of association in our small population of X-ALD patients. No
significant association was detected with any of the six SNPs of
CD1B (Table 2).
In the CD1D gene, three intronic SNPs with a MAF,0.10 were
associated with X-ALD phenotypes at the 0.05 significance level
(Table 2). For all of them, the minor allele was more frequent in
the AMN sample population (rs859008 C/T, PFisher=0.018,
empirical P=0.020; rs859009 C/G, PFisher=0.010, empirical
P=0.010; rs859013 A/G, PFisher=0.014, empirical P=0.016).
These three SNPs were in strong LD (r
2$0.87).
Using HapMap (http://hapmap.ncbi.nlm.nih.gov) genotypic
data from European individuals, we detected a strong LD between
three SNPs of CD1D (rs859008, rs859009 and rs859013) and seven
SNPs located 3.2-kb upstream from the transcription start site of
CD1D (r
2$0.90). This raises the possibility that the previous
associations of rs859008, rs859009 and rs859013 with X-ALD
phenotypes resulted from a LD with a possible causal SNP
localized in this region. The seven SNPs in the upstream region of
CD1D formed a 1.3-kb block of strong LD (r
2$0.93). BLAST tool
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and the ENSEMBL ge-
nome browser (http://www.ensembl.org/Homo_sapiens/Info/
Index) revealed that this 1.3-kb region overlaps with a known
pseudogene (ENSEMBL identifier: ENSG00000227295). We
therefore genotyped these seven SNPs in patients with AMN
and CCALD. All SNPs were detected in the X-ALD population,
with a similar MAF (,0.10). The seven SNPs also formed a block
of total LD in the X-ALD population (r
2=1, Figure S1) and were
also in LD with rs859008, rs859009 and rs859013 in X-ALD
patients (r
2$0.74, Figure S1). Consequently, these seven SNPs
showed associations with X-ALD phenotypes, but the significance
levels were lower than with rs859008, rs859009 and rs859013
(Table S2).
Discussion
Besides major histocompatibility complex (MHC) class I and II
molecules, a third lineage of antigen-presenting molecules that
bind lipid and glycolipid antigens rather than peptides is mediated
by the family of CD1 proteins [10]. The molecular basis for the
phenotypic variability of X-ALD is still unclear. However, given
the putative role of lipid antigens in the development of cerebral
demyelinating forms of X-ALD that are characterized by severe
neuroinflammation [6], we wondered whether a polymorphism in
one or several CD1 genes may influence the incidence of
inflammatory demyelination in X-ALD. We ‘‘tagged’’ the entire
region including the five CD1 genes in 139 X-ALD patients
presenting either CCALD or pure AMN with 23 selected tag SNPs
identified using the HapMap SNP database. Only one common
SNP (rs973742 A/G; MAF=0.40 in the X-ALD population)
located in the downstream region of CD1D showed evidence of an
allelic association with X-ALD phenotypes. The minor allele A
had a higher prevalence in AMN than in CCALD patients 0.50 vs
0.33 respectively; x
2=7.6 P=0.006 Odds ratio=0.50). Three
other intronic SNPs (rs859008, rs859009 and rs859013) of CD1D
gene showed weaker associations (P value ranging from 0.010 to
0.018) with X-ALD phenotypes. These three SNPs are in strong
LD with a block of seven SNPs overlapping a known pseudogene
in the upstream region of CD1D, but we did not detect stronger
association between any of these seven SNPs and X-ALD
phenotypes.
Re-sequencing of the CD1D as well as CD1B genes (in which
additional SNPs showed weaker allelic association with X-ALD
phenotype) in 50 control individuals failed to detect new SNPs/
genetic variants that were not already identified in the European
HapMap population. One may wonder whether we missed a SNP
in the X-ALD population that would not be described in SNP
Table 2. Allelic analyses of CD1D and CD1B variants in the CCALD and AMN patients.
SNP (dbSNP31) gene MAF MAF AMN MAF CCALD x
2 P value empirical P value
b Odds ratio [CI95%]
rs859008 CD1D 0.09 0.14 0.06 5.99 0.018
a 0.020 0.36 [0.16 ; 0.84]
rs859009 0.09 0.15 0.06 7.13 0.010
a 0.010 0.34 [0.15 ; 0.77]
rs859013 0.09 0.14 0.05 6.9 0.014
a 0.016 0.33 [0.14 ; 0.78]
rs422236 0.41 0.42 0.40 0.12 0.73 - 0.92 [0.56 ; 1.50]
rs11583390 CD1B 0.03 0.03 0.03 - - - -
rs16840096 0.11 0.16 0.09 3.22 0.073 0.118 0.51 [0.24 ; 1.08]
rs3176842 0.17 0.17 0.16 0.05 0.82 - 0.93 [0.49 ; 1.78]
rs35841099 0.004 0.01 0 - - - -
rs962879 0.12 0.17 0.09 3.64 0.056 0.106 0.49 [0.23 ; 1.31]
rs62642468 0.03 0.05 0.02 - - - -
a: The Fisher’s exact test was used for SNP with a Minor Allele Frequency (MAF),0.10.
b: Permutation-based empirical P value were calculated for SNP showing a trend of association (P value,0.10).
doi:10.1371/journal.pone.0029872.t002
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screened. Our results clearly argue against this hypothesis. First,
we did not detect any new SNP in the healthy control population
compared to those described in SNP databases. Second, the minor
allele frequencies of detected variants in the control population
were very similar to those found in SNP databases and in the X-
ALD population (Table S1). Third, the pattern of LD between the
SNPs of CD1D and its 59 region was the same in the European
HapMap population and in the X-ALD population. All together,
these data are in favor of a similar pattern of genetic variations in
the CD1 locus between the European HapMap population, the
control population, and the X-ALD population. It is therefore
unlikely that a frequent and non described SNP existing only in
the CCALD or AMN populations has been missed, although we
cannot exclude the possibility that rare variants in CD1D and
CD1B may exist in CCALD and AMN patients since our approach
did not allow the detection of such variants. Our failure to detect
new SNPs confirms the low level of allelic polymorphism in the
CD1 genes [12]. This is in line with the fact that, in contrast to the
MHC class I and class II proteins, the CD1 antigen presenting
system, which has diverged early in vertebrate evolution from
MHC antigen presenting molecules, is a simpler system with a
character that has evolved little from the primordial antigen
presenting function [13].
The functional role of rs973742 is unknown. CD1d molecules
are believed to present glycolipid antigens to a distinct lineage of T
cells called iNKT cells, but the exact nature of the endogenous
ligand(s) recognized by these cells remains elusive [14]. Data
obtained in experimental autoimmune encephalomyelitis (EAE)
mice support the crucial role of iNKT cells in the pathogenesis of
inflammatory demyelinating diseases [11]. Patients with relapsing
multiple sclerosis have smaller numbers of circulating iNKT cells
than healthy controls and their function is linked to the severity of
the disease [11]. Recently, we showed that the frequency of iNKT
cells in peripheral blood mononuclear cells from X-ALD patients
was significantly lower than in healthy individuals [15]. X-ALD
iNKT cells are also more immature and CD1d expression is
decreased in X-ALD B lymphocytes. Cytokine production by X-
ALD iNKT cells is however normal and no correlation was
observed between iNKT cell maturation or iNKT cell frequency
and X-ALD phenotypes. The association between the CD1D
genetic variant (rs973742) and X-ALD phenotype may warrant
further studies on the CD1d molecule itself, in particular on how
this variant may affect CD1d recycling between the plasma
membrane and the intracellular compartment [13]. Furthermore,
we cannot exclude the possibility that rs973742 may be in linkage
disequilibrium with a causative variant at distance from the CD1
locus or with an undetected rare variant of CD1D present only in
the ALD population. Although our results do not suggest that
genetic variants of CD1 genes contribute markedly to the
phenotypic variance of X-ALD, CD1d and other CD1 molecules
may still have an important role in the inflammatory process
observed in CCALD.
In the absence of biomarkers correlated with X-ALD pheno-
types, the identification of genetic variants contributing to the
phenotypic variance of X-ALD remains a huge task, as in nearly
all rare Mendelian diseases. Using a candidate gene strategy,
which has major limitations, no genetic variants have been found
to influence significantly X-ALD phenotypes up to now [16,17].
The results reported herein for the CD1 genes do not differ
significantly from previous studies in this field. Although CCALD
and AMN phenotypes can be clearly distinguished at the
neuropathological level, the failure to detect genetic variants
having a strong influence on these two X-ALD phenotypes could
be due to the sum of many rare genetic variant interactions, as
observed in many multifactorial diseases [18].
Materials and Methods
Patients and healthy volunteers
The population of X-ALD cases included 52 patients with
‘‘pure’’ AMN and 87 patients with childhood cerebral ALD
(CCALD), all of European origin (Caucasians). Patients with
‘‘pure’’ AMN are adult males .45 years of age with isolated spinal
cord disease with or without adrenal insufficiency but without
cerebral demyelinating lesions at brain MRI. Longitudinal follow-
up of 684 patients with X-ALD indicates that the risk to develop
cerebral demyelinating lesions drop to less than 5% after the age of
45 years (P. Aubourg, unpublished results). Patients with CCALD
are boys who developed inflammatory cerebral demyelinating
disease before 12 years of age. Thus, two groups of X-ALD
patients with extreme phenotypes (CCALD and pure AMN) were
defined for this study. DNAs from 50 unrelated healthy volunteers
of European origin were used as ‘‘control’’ to screen for new
sequence variations in the CD1D and CD1B genes by sequence
analyses. The DNA sample collection was declared to INSERM
and approved by the local ethical committee (Comite ´d e
Protection des Personnes Ile-de-France III). Informed written
consents were obtained from all X-ALD and control patients or
their legal guardians.
Tagging analyses of the CD1 locus and linkage
disequilibrium (LD) studies
The pattern of LD across the CD1 genes cluster was studied in a
400-kb large region encompassing the five CD1 genes and
neighboring genes. All X-ALD cases being of European origin,
we used HapMap SNP data (the International HapMap Project
(http://hapmap.ncbi.nlm.nih.gov)/Public Release #22) from the
CEU HapMap sample (European ancestry) to examine LD block
structure with the program Haploview (http://www.broadinstitute.
org/haploview) [19]. The r
2 for all pairs of SNPs was calculated to
evaluate the presence of LD between the different CD1 genes, and
between CD1 genes with non-CD1 genes. After excluding LD
between polymorphisms of CD1 genes and neighboring genes (data
not shown), we used the Tagger program implemented in
Haploview to select SNPs that efficiently tagged all common
variations in the 200-kb region encompassing only the five CD1
genes. We chose an aggressive tagging procedure to select tag SNPs,
requiring a minimum Minor Allele Frequency (MAF) of 0.05 and a
minimum estimated r
2 between the tagged and tag SNPs sets to be
$0.90 that allowed only a slight loss of power in typing only tag
SNPs. From the original set of 115 common SNPs in the European
sample (MAF.0.05), 23 tag SNPs were selected (Table 1). The
mean r
2 between tagged and the tag SNPs set was 0.995.
Identification of variants in CD1D and CD1B genes
CD1D and CD1B genes were sequenced in 50 unrelated
controls. Two regions, each covering one of these two genes +
1-kb in untranslated regions (UTRs) were targeted for a
Polymerase-Chain-Reaction (PCR) amplification using the follow-
ing primers: for CD1D,5 9-GCCTGGCCTCTGTTGATAAA-
CAAA-39 and 59-CAGGGTCTCCCTCTGTCATCCTTA-39;
for CD1B,5 9-GAGGCAGTAACAGACTGCCAG-39 and 59-
GCCAAGGGTGGTTTTCTCCAAAG-39. PCRs were carried
out using the Expand Long Range PCR kit (Roche Applied
Science, Switzerland), and purified before the sequence analyses
(Multiscreen HTS plates, Millipore, USA) following manufactur-
er’s instructions. Primers used for sequencing are available upon
CD1 Gene Polymorphisms and X-ALD
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Terminator v1.1 kit (Applied Biosystems, USA). Base calling was
realized on the ABI 377 sequencer (Applied Biosystems, USA). All
polymorphisms were confirmed using double sense sequencing.
Genotyping of polymorphisms in the X-ALD sample
population
TaqManH SNP Genotyping Assay-by-Design method (Applied
Biosystems, USA) was used to genotype 39 of 40 SNPs (23 tag
SNPs, nine SNPs in CD1D/CD1B genes, seven SNPs in the
upstream region of CD1D) in the X-ALD sample population with
an allele-specific hybridization approach. Pre-designed and
Custom probes were designed by Applied Biosystems (available
upon request). PCR amplification was carried out according to the
manufacturer’s instructions. The PCR was followed by allelic
discrimination using the ABI Prism 7900 to perform plate reading.
Automated allele calling was performed by allelic discrimination
plots with ABI SDS software version 2.2 (Applied Biosystems,
USA).
The SNP rs859009 was genotyped using the PCR-Restriction-
Fragment-Length Polymorphisms (RFLP) method, as this poly-
morphism creates a restriction site for the restriction enzyme
AvrII. The sequence containing the SNP rs859009 was first
amplified using the following primers: forward, 59-AAAAGAGT-
GAGGGAGAGGGAGGTG-39 and reverse, 59-CAACGTGT-
GGGACGCTTTACAAC-39. After digestion of PCR products
with AvrII (Ozyme, France) and 2% agarose gel (Euromedex,
France) electrophoresis, two bands of 457-bp and 251-bp can be
identified when the CC genotype is present; one band of 708-bp
for the GG genotype; three bands for heterozygous CG. Profiles of
digestion were checked by a sequencing of PCR products from six
patients. For all SNPs, the genotyping rate was $97%. No
deviation of the Hardy-Weinberg equilibrium was detected using a
significance threshold of 0.05 for all tested SNPs.
Statistical analysis
We used the PLINK software to carry out statistical analyses
(http://pngu.mgh.harvard.edu/purcell/plink/) [20]. For the as-
sociation analyses, the statistical significance of differences in allele
frequencies between AMN and CCALD patients was evaluated
using an allelic chi-square test (x
2 Pearson), with degree of freedom
equal to one. For SNPs with MAF,0.10 in the X-ALD sample, an
exact P-value was computed using the Fisher’s exact test. To take
into account the small size of the X-ALD sample population, and
to deal with rare variants, an empirical P-value was computed
using an adaptive permutation procedure for SNPs which showed
trends (P,0.10) or evidences (P,0.05) of associations. Since some
of the tag SNPs were in LD in the X-ALD sample population
(Figure 1), accounting for the number of tests using a simple
Bonferroni correction is expected to be too much conservative. An
effective number of independent SNPs was therefore calculated by
the method proposed by Li and Ji [21] implemented in the
SNPSpD software [22]. We found that the 21 tag SNPs included
in statistical analyses (exclusion of two tag SNPs with MAF,0.05)
corresponded to 12 effective independent ones. The corresponding
Bonferroni-corrected significance threshold was 0.004.
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